Generics - Pharmaceutical, Neurological

Filter

Popular Filters

1 to 25 of 54 results

Avanir Pharma patent settlement with Wockhardt

08-09-2013

USA-based Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into a settlement agreement with the US unit…

Avanir PharmaceuticalsGenericsLegalNeurologicalNorth AmericaNuedextaPatentsPharmaceuticalWockhardt

Avanir Pharma settles Nuedexta patent litigation with Actavis

03-09-2013

USA-based Avanir Pharmaceuticals (Nasdaq: AVNR) says that it has entered into a settlement agreement…

ActavisAvanir PharmaceuticalsGenericsLegalNeurologicalNorth AmericaNuedextaPatentsPharmaceutical

Teva to drop development of Nuvigil in bipolar 1 disorder

31-08-2013

Israel-based leading generics company Teva Pharmaceutical Industries (NYSE: TEVA) has released disappointing…

armodafinilCephalonGenericsNeurologicalNuvigilPharmaceuticalResearchTeva Pharmaceutical Industries

Avanir agrees settlement with Sandoz over Nuedexta

14-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into a settlement agreement with Swiss…

Avanir PharmaceuticalsGenericsLicensingNeurologicalNorth AmericaNuedextaPharmaceuticalSandoz

Lundbeck/Takeda's Brintellix has blockbuster potential

02-08-2013

Denmark CNS drug specialist Lundbeck (LUND: CO) and partner Japanese drug major Takeda Pharmaceutical's…

BrintellixedivoxetineEli LillyFetzimaForest LaboratoriesGenericsGlobalLundbeckMarkets & MarketingNeurologicalPharmaceuticalPierre FabreTakeda Pharmaceuticals

Actavis debuts new formulations of Fioricet

30-07-2013

US generics major Actavis (NYSE: ACT) has launched new formulations of Fioricet (butalbital, acetaminophen…

AcetaminophenActavisFioricetFioricet with CodeineGenericsMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

US Appeals Court overturns Copaxone patent decision

28-07-2013

Israel-based generics giant Teva Pharmaceutical Industries ((NYSE: TEVA) said on Friday (July 26) that…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaNovartisPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Mylan strikes deal for Parkinson's disease drug Stalevo

26-07-2013

US generics firm Mylan (Nasdaq: MYL) and Finland-based drugmaker Orion Corp (Nasdaq OMX Helsinki: ORNAV)…

GenericsLicensingMylan LaboratoriesNeurologicalNorth AmericaOrion CorpPharmaceuticalStalevo

New Zealand approves proposals diazepam, gabapentin and naltrexone listing

12-07-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of proposals relating…

Asia-PacificdiazepamgabapentinGenericsnaltrexoneNeurologicalPharmaceuticalRegulation

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

June meeting highlights from EMA Pharmacovigilance Risk Assessment Committee

14-06-2013

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has made several recommendations…

codeinediclofenacEuropeflupirtineGenericshydroxyethyl-starchNeurologicalPharmaceuticalRegulation

US FDA to allow generic copies of Endo's Opana

13-05-2013

Endo Health Solutions (Nasdaq: ENDP) announced Friday (May 10) that the US Food and Drug Administration…

Endo Health SolutionsEndo PharmaceuticalsGenericsNeurologicalNorth AmericaOpana ERPharmaceuticalRegulation

US FDA warns pregnant women to not use valproate migraine prevention medicines

07-05-2013

The US Food and Drug Administration is alerting health care providers and patients that medications including…

Abbott LaboratoriesGenericsNeurologicalNorth AmericaNoven PharmaceuticalsPharmaceuticalRegulationSanofivalproate Sodium Injection

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

UK's OFT accuses GlaxoSmithKline of "market abuse"

19-04-2013

The UK's Office of Fair Trading (OFT) today (April 19) issued a Statement of Objections to certain pharmaceutical…

AlpharmaEuropeGenericsGlaxoSmithKlineLegalMarkets & MarketingNeurologicalNorton HealthcarePaxilPharmaceuticalPricingSeroxat

CNS therapeutics market facing downward pressure as branded drugs continue to expire

08-04-2013

The global central nervous system (CNS) therapeutics market has been forecast to reach $133 billion by…

GenericsGlobalMarkets & MarketingNeurologicalPharmaceutical

Briefs: Glenmark challenges Bayer patent; FDA delays Merck & Co's sugammadex

18-03-2013

Indian drugmaker Glenmark Generics confirms that it seeking US Food and Drug Administration approval…

BayerBridionDermatologicalsFinacea GelGenericsGlenmark PharmaceuticalsMerck & CoNeurologicalNorth AmericaPatentsPharmaceuticalRegulationsugammadex

Mylan settles with Shionogi and Andrx over Fortamet; Merck & Co diagnostics deal with Luminex

14-03-2013

US generic drugmaker Mylan (Nasdaq: MYL) has entered into a settlement agreement with Japan's Shionogi…

AndrxDiabetesFortametGenericsLuminexMerck & CoMylan LaboratoriesNeurologicalNorth AmericaPatentsPharmaceuticalShionogi

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

25-02-2013

Belgium drug developer Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with…

AblynxGenericsidebenoneIdecortexLicensingMarkets & MarketingNeurologicalOncologyPharmaceuticalResearchSolent PharmaSpirogen

US Court of Appeals confirms validity of AstraZeneca' Seroquel XR patent

15-02-2013

AstraZeneca announced that, on 14 February 2013, the United States Court of Appeals for the Federal Circuit…

AstraZenecaGenericsLegalNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XR

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study

10-02-2013

Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis

01-02-2013

The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

1 to 25 of 54 results

Back to top